Amprion and Prema Cognition have formed a collaboration pairing a 10–15 minute digital memory assessment with seed amplification biomarker assays for neurodegenerative disease. The digital test measures memory precision rather than simple recall, aiming to flag individuals with subjective cognitive decline who score normally on conventional screening and may warrant confirmatory molecular testing. No performance data, timeline, or cost structure has been disclosed.
Key Points
- Digital memory precision test screens before molecular biomarker confirmation
- Targets subjective cognitive decline missed by standard cognitive screening
- No published performance figures, pathway timeline, or cost details yet
Longevity Analysis
The sequencing matters more than either tool alone: a low-friction, repeatable assessment that can be run at intervals, followed by a highly specific assay that identifies underlying pathology. Cognitive change is among the most frequently mislabeled signals in adult medicine, dismissed as normal aging until structural loss is advanced, and a tiered approach shifts the detection window years earlier. For anyone tracking brain health across decades, the value lies in establishing a personal baseline early and repeating the measurement consistently, long before a single result carries diagnostic weight.
Original published by Longevity.Technology, by Kyle Umipig.